** Shares of Neuren Pharmaceuticals NEU.AX up 16% at A$10.7, their biggest intraday percentage gain since December 18, 2023
** Stock is top gainer in the ASX 200 benchmark index .AXJO, which is up 0.6%
** The drugmaker says primary endpoints for its Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome (PMS), a genetic disorder, confirmed at a meeting with the U.S. Food and Drug Administration
** Stock down 26.5% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。